問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of General Internal Medicine

Division of Otolaryngology

Division of Infectious Disease

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

鄭偉宏Cheng, Wei-Hong
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

Recruiting Trial

50Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭偉宏

List

81Cases

2020-10-15 - 2025-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2024-07-31 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting3Sites

2020-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-01-11 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2024-09-15 - 2027-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2020-11-18 - 2024-12-31

Phase II

Completed
An Exploratory, Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase IIa Study to Assess the Analgesic Activity of PAX-1 in Patients with Persistent Cancer Pain.

  • Condition/Disease

    Persistent Cancer Pain

  • Test Drug

    PAX-1

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2024-10-25 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-09-22 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2016-12-29 - 2023-09-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

劉良智
China Medical University Hospital-Taipei

未分科

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB